Giannino Del Sal

List of Publications by Year
in descending order

130	12,151	23567	26613
papers	citations	58 h-index	107 g-index

131	131	131	15957
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nature Cell Biology, 2002, 4, 11-19.	10.3	636
2	Metabolic control of YAP and TAZ by the mevalonate pathway. Nature Cell Biology, 2014, 16, 357-366.	10.3	630
3	Mutant p53 as a guardian of the cancer cell. Cell Death and Differentiation, 2019, 26, 199-212.	11.2	523
4	Dynamic landscape and regulation of RNA editing in mammals. Nature, 2017, 550, 249-254.	27.8	495
5	Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1. EMBO Journal, 1999, 18, 6462-6471.	7.8	463
6	Protein Kinase C ÃŸ and Prolyl Isomerase 1 Regulate Mitochondrial Effects of the Life-Span Determinant p66 ^{Shc}. Science, 2007, 315, 659-663.	12.6	448
7	The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults. Nature, 2002, 419, 853-857.	27.8	390
8	The Transcriptional Coactivator Yes-Associated Protein Drives p73 Gene-Target Specificity in Response to DNA Damage. Molecular Cell, 2005, 18, 447-459.	9.7	318
9	The growth arrest-specific gene, gas1, is involved in growth suppression. Cell, 1992, 70, 595-607.	28.9	263
10	A one-tube plasmid DNA mini-preparation suitable for sequencing. Nucleic Acids Research, 1988, 16, 9878-9878.	14.5	258
11	A Pin1/Mutant p53 Axis Promotes Aggressiveness inÂBreast Cancer. Cancer Cell, 2011, 20, 79-91.	16.8	256
12	p53 at the endoplasmic reticulum regulates apoptosis in a Ca ²⁺ -dependent manner. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 1779-1784.	7.1	247
13	The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis, 2012, 33, 2007-2017.	2.8	236
14	iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72â€“polymorphic p53. Nature Genetics, 2006, 38, 1133-1141.	21.4	228
15	Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer. Nature Cell Biology, 2016, 18, 897-909.	10.3	205
16	Physical Interaction with Human Tumor-derived p53 Mutants Inhibits p63 Activities. Journal of Biological Chemistry, 2002, 277, 18817-18826.	3.4	203
17	Direct p53 Transcriptional Repression: In Vivo Analysis of CCAAT-Containing G 2 /M Promoters. Molecular and Cellular Biology, 2005, 25, 3737-3751.	2.3	202
18	p53-family proteins and their regulators: hubs and spokes in tumor suppression. Cell Death and Differentiation, 2010, 17, 901-911.	11.2	196

#	Article	IF	Citations
19	BRD7 is a candidate tumour suppressor gene required for p53 function. Nature Cell Biology, 2010, 12, 380-389.	10.3	194
20	Pin1 Links the Activities of c-Abl and p300 in Regulating p73 Function. Molecular Cell, 2004, 14, 625-636.	9.7	165
21	Sterol regulatory element binding protein 1 couples mechanical cues and lipid metabolism. Nature Communications, 2019, 10, 1326.	12.8	158
22	The prolyl-isomerase Pin1 is a Notch1 target that enhances Notch1 activation in cancer. Nature Cell Biology, 2009, 11, 133-142.	10.3	154
23	<scp>YAP</scp> enhances the proâ€proliferative transcriptional activity of mutant p53 proteins. EMBO Reports, 2016, 17, 188-201.	4.5	154
24	The prolyl isomerase Pin1 orchestrates p53 acetylation and dissociation from the apoptosis inhibitor iASPP. Nature Structural and Molecular Biology, 2007, 14, 912-920.	8.2	147
25	HMGA1 promotes metastatic processes in basal-like breast cancer regulating EMT and stemness. Oncotarget, 2013, 4, 1293-1308.	1.8	145
26	Transcriptional Activation of the Cyclin A Gene by the Architectural Transcription Factor HMGA2. Molecular and Cellular Biology, 2003, 23, 9104-9116.	2.3	140
27	Rrs1 Is Involved in Endoplasmic Reticulum Stress Response in Huntington Disease. Journal of Biological Chemistry, 2009, 284, 18167-18173.	3.4	137
28	Mutant p53 Reprograms TNF Signaling in Cancer Cells through Interaction with the Tumor Suppressor DAB2IP. Molecular Cell, 2014, 56, 617-629.	9.7	136
29	Prolylâ€isomerase Pin1 controls normal and cancer stem cells of the breast. EMBO Molecular Medicine, 2014, 6, 99-119.	6.9	130
30	Glucocorticoid receptor signalling activates YAP in breast cancer. Nature Communications, 2017, 8, 14073.	12.8	129
31	Caspase-dependent Regulation of Histone Deacetylase 4 Nuclear-Cytoplasmic Shuttling Promotes Apoptosis. Molecular Biology of the Cell, 2004, 15, 2804-2818.	2.1	128
32	Pin1 and WWP2 regulateGluR2Q/R site RNA editing by ADAR2 with opposing effects. EMBO Journal, 2011, 30, 4211-4222.	7.8	115
33	Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer. Cell Cycle, 2013, 12, 1679-1687.	2.6	109
34	The cytoplasmic side of p53's oncosuppressive activities. FEBS Letters, 2014, 588, 2600-2609.	2.8	104
35	Mechanical cues control mutant p53 stability through a mevalonateâ€“RhoA axis. Nature Cell Biology, 2018, 20, 28-35.	10.3	104
36	A covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action. Nature Communications, 2017, 8, 15772.	12.8	102

#	Article	IF	Citations
37	Concerted action of cellular JNK and Pin1 restricts HIV-1 genome integration to activated CD4+ T lymphocytes. Nature Medicine, 2010, 16, 329-333.	30.7	101
38	A proline-rich motif in p53 is required for transactivation- independent growth arrest as induced by Gas1. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 4675-4680.	7.1	88
39	HMGA1 Inhibits the Function of p53 Family Members in Thyroid Cancer Cells. Cancer Research, 2006, 66, 2980-2989.	0.9	87
40	Post-phosphorylation prolyl isomerisation of gephyrin represents a mechanism to modulate glycine receptors function. EMBO Journal, 2007, 26, 1761-1771.	7.8	86
41	Mutant p53 tunes the NRF2-dependent antioxidant response to support survival of cancer cells. Oncotarget, 2018, 9, 20508-20523.	1.8	86
42	The prolyl-isomerase Pin1 activates the mitochondrial death program of p53. Cell Death and Differentiation, 2013, 20, 198-208.	11.2	83
43	Some p53-binding proteins that can function as arbiters of life and death. Cell Death and Differentiation, 2006, 13, 984-993.	11.2	82
44	CDNA cloning of the neutrophil bactericidal peptide indolicidin. Biochemical and Biophysical Research Communications, 1992, 187, 467-472.	2.1	76
45	Prolyl Isomerase PIN1 Regulates DNA Double-Strand Break Repair by Counteracting DNA End Resection. Molecular Cell, 2013, 50, 333-343.	9.7	76
46	Targeting prolyl-isomerase Pin1 prevents mitochondrial oxidative stress and vascular dysfunction: insights in patients with diabetes. European Heart Journal, 2015, 36, 817-828.	2.2	75
47	Mutant p53 Gains Its Function via c-Myc Activation upon CDK4 Phosphorylation at Serine 249 and Consequent PIN1 Binding. Molecular Cell, 2017, 68, 1134-1146.e6.	9.7	73
48	The Cell Cycle-regulated Protein Human GTSE-1 Controls DNA Damage-induced Apoptosis by Affecting p53 Function. Journal of Biological Chemistry, 2003, 278, 30356-30364.	3.4	71
49	Mutant p53: One, No One, and One Hundred Thousand. Frontiers in Oncology, 2015, 5, 289.	2.8	71
50	Autoregulatory control of the p53 response by caspase-mediated processing of HIPK2. EMBO Journal, 2006, 25, 1883-1894.	7.8	69
51	Notch is a direct negative regulator of the DNA-damage response. Nature Structural and Molecular Biology, 2015, 22, 417-424.	8.2	68
52	Mutations in Proline 82 of p53 Impair Its Activation by Pin1 and Chk2 in Response to DNA Damage. Molecular and Cellular Biology, 2005, 25, 5380-5388.	2.3	66
53	Ser46 phosphorylation and prolyl-isomerase Pin1-mediated isomerization of p53 are key events in p53-dependent apoptosis induced by mutant huntingtin. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 17979-17984.	7.1	64
54	MiR-181 family-specific behavior in different cancers: a meta-analysis view. Cancer and Metastasis Reviews, 2018, 37, 17-32.	5.9	63

#	Article	IF	Citations
55	cDNA sequence analysis of an antibiotic dodecapeptide from neutrophils. FEBS Letters, 1992, 314, 187-190.	2.8	61
56	Transactivation properties of c-Myb are critically dependent on two SUMO-1 acceptor sites that are conjugated in a PIASy enhanced manner. FEBS Journal, 2003, 270, 1338-1348.	0.2	61
57	Modification of the erythroid transcription factor GATA-1 by SUMO-1. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 8870-8875.	7.1	61
58	The Transcriptional Repressor hDaxx Potentiates p53-dependent Apoptosis. Journal of Biological Chemistry, 2004, 279, 48013-48023.	3.4	61
59	A genome-scale protein interaction profile of Drosophila p53 uncovers additional nodes of the human p53 network. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 6322-6327.	7.1	61
60	The growth suppressinggas1product is a GPI-linked protein. FEBS Letters, 2000, 481, 152-158.	2.8	60
61	Inhibition of the Peptidyl-Prolyl-Isomerase Pin1 Enhances the Responses of Acute Myeloid Leukemia Cells to Retinoic Acid via Stabilization of RARÎ± and PML-RARÎ±. Cancer Research, 2009, 69, 1016-1026.	0.9	57
62	Mutant p53 improves cancer cellsâ€™ resistance to endoplasmic reticulum stress by sustaining activation of the UPR regulator ATF6. Oncogene, 2019, 38, 6184-6195.	5.9	56
63	Targeting mutant p53 in cancer: a long road to precision therapy. FEBS Journal, 2017, 284, 837-850.	4.7	55
64	MDP, a database linking drug response data to genomic information, identifies dasatinib and statins as a combinatorial strategy to inhibit YAP/TAZ in cancer cells. Oncotarget, 2015, 6, 38854-38865.	1.8	54
65	MCM7and its hosted miR-25, 93 and 106b cluster elicit YAP/TAZ oncogenic activity in lung cancer. Carcinogenesis, 2017, 38, 64-75.	2.8	52
66	Mutant p53 induces Golgi tubulo-vesiculation driving a prometastatic secretome. Nature Communications, 2020, 11, 3945.	12.8	52
67	PIN1 in breast development and cancer: a clinical perspective. Cell Death and Differentiation, 2017, 24, 200-211.	11.2	51
68	Aggresome-forming TTRAP mediates pro-apoptotic properties of Parkinson's disease-associated DJ-1 missense mutations. Cell Death and Differentiation, 2009, 16, 428-438.	11.2	49
69	Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer. EMBO Molecular Medicine, 2013, 5, 707-722.	6.9	49
70	Regulation of p53 functions: let's meet at the nuclear bodies. Current Opinion in Cell Biology, 2003, 15, 351-357.	5.4	46
71	Pin1-dependent signalling negatively affects GABAergic transmission by modulating neuroligin2/gephyrin interaction. Nature Communications, 2014, 5, 5066.	12.8	45
72	hGTSE-1 Expression Stimulates Cytoplasmic Localization of p53. Journal of Biological Chemistry, 2004, 279, 11744-11752.	3.4	44

#	Article	IF	Citations
73	Mutant p53 inhibits miRNA biogenesis by interfering with the microprocessor complex. Oncogene, 2016, 35, 3760-3770.	5.9	43
74	Breast Cancer Organoids Model Patient-Specific Response to Drug Treatment. Cancers, 2020, 12, 3869.	3.7	43
75	p53 is involved in the p120E4F-mediated growth arrest. Oncogene, 2000, 19, 188-199.	5.9	42
76	Peptide Aptamers Targeting Mutant p53 Induce Apoptosis in Tumor Cells. Cancer Research, 2008, 68, 6550-6558.	0.9	42
77	Autophosphorylation and Pin1 binding coordinate DNA damage-induced HIPK2 activation and cell death. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E4203-E4212.	7.1	42
78	The Prolyl Isomerase Pin1 Affects Che-1 Stability in Response to Apoptotic DNA Damage. Journal of Biological Chemistry, 2007, 282, 19685-19691.	3.4	40
79	Mutant p53 potentiates the oncogenic effects of insulin by inhibiting the tumor suppressor DAB2IP. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 7623-7628.	7.1	38
80	Parkinson Disease-associated DJ-1 Is Required for the Expression of the Glial Cell Line-derived Neurotrophic Factor Receptor RET in Human Neuroblastoma Cells. Journal of Biological Chemistry, 2010, 285, 18565-18574.	3.4	37
81	Evidence of enhancement of theras oncogene protein product (p21) in a spectrum of human tumors. International Journal of Cancer, 1989, 43, 431-435.	5.1	35
82	p73 as a Pharmaceutical Target for Cancer Therapy. Current Pharmaceutical Design, 2011, 17, 578-590.	1.9	33
83	DLX5, FGF8 and the Pin1 isomerase control Î”Np63Î± protein stability during limb development: a regulatory loop at the basis of the SHFM and EEC congenital malformations. Human Molecular Genetics, 2014, 23, 3830-3842.	2.9	33
84	Regulation of mitochondrial apoptosis by Pin1 in cancer and neurodegeneration. Mitochondrion, 2014, 19, 88-96.	3.4	33
85	Cell-autonomous and cell non-autonomous downregulation of tumor suppressor DAB2IP by microRNA-149-3p promotes aggressiveness of cancer cells. Cell Death and Differentiation, 2018, 25, 1224-1238.	11.2	33
86	p53-Mediated downregulation of H ferritin promoter transcriptional efficiency via NF-Y. International Journal of Biochemistry and Cell Biology, 2008, 40, 2110-2119.	2.8	32
87	Modification of Drosophila p53 by SUMO Modulates Its Transactivation and Pro-apoptotic Functions. Journal of Biological Chemistry, 2008, 283, 20848-20856.	3.4	32
88	Activation of the p53 pathway down-regulates the osteoprotegerin expression and release by vascular endothelial cells. Blood, 2008, 111, 1287-1294.	1.4	30
89	Gene regulation and tumor suppression by the bromodomain-containing protein BRD7. Cell Cycle, 2010, 9, 2849-2853.	2.6	29
90	Impairment of the Pin1/E2F1 axis in the anti-proliferative effect of bortezomib in hepatocellular carcinoma cells. Biochimie, 2015, 112, 85-95.	2.6	29

#	Article	IF	Citations
91	The complexity of cell proliferation control in mammalian cells. Current Opinion in Cell Biology, 1991, 3, 276-281.	5.4	28
92	Proline Isomerase Pin1 Represses Terminal Differentiation and Myocyte Enhancer Factor 2C Function in Skeletal Muscle Cells. Journal of Biological Chemistry, 2010, 285, 34518-34527.	3.4	28
93	Pin1 is required for sustained B cell proliferation upon oncogenic activation of Myc. Oncotarget, 2016, 7, 21786-21798.	1.8	28
94	The PML nuclear bodies-associated protein TTRAP regulates ribosome biogenesis in nucleolar cavities upon proteasome inhibition. Cell Death and Differentiation, 2012, 19, 488-500.	11.2	25
95	Interaction of p53 with prolyl isomerases: Healthy and unhealthy relationships. Biochimica Et Biophysica Acta - General Subjects, 2015, 1850, 2048-2060.	2.4	24
96	Prolyl isomerase Pin1 and protein kinase HIPK2 cooperate to promote cortical neurogenesis by suppressing Groucho/TLE:Hes1-mediated inhibition of neuronal differentiation. Cell Death and Differentiation, 2014, 21, 321-332.	11.2	23
97	KeePinâ€™ the p53 Family in Good Shape. Cell Cycle, 2004, 3, 903-909.	2.6	22
98	Wiring the oncogenic circuitry: Pin1 unleashes mutant p53. Oncotarget, 2011, 2, 654-656.	1.8	22
99	The stiff RhoAd from mevalonate to mutant p53. Cell Death and Differentiation, 2018, 25, 645-647.	11.2	21
100	Oncogenic Hijacking of the PIN1 Signaling Network. Frontiers in Oncology, 2019, 9, 94.	2.8	21
101	Disarming mutant p53 oncogenic function. Pharmacological Research, 2014, 79, 75-87.	7.1	20
102	Dynamic regulation of Pin1 expression and function during zebrafish development. PLoS ONE, 2017, 12, e0175939.	2.5	17
103	Adenosine deaminase, a key enzyme in DNA precursors control, is a new p73 target. Oncogene, 2003, 22, 8738-8748.	5.9	16
104	A simple discontinuous buffer system for increased resolution and speed in gel electrophoretic analysis of DNA sequence. Nucleic Acids Research, 1990, 18, 204-204.	14.5	15
105	Effects of Pin1 Loss in HdhQ111 Knock-in Mice. Frontiers in Cellular Neuroscience, 2016, 10, 110.	3.7	15
106	Isoprenylcysteine carboxy methyltransferase (ICMT) is associated with tumor aggressiveness and its expression is controlled by the p53 tumor suppressor. Journal of Biological Chemistry, 2019, 294, 5060-5073.	3.4	15
107	The prolyl-isomerase PIN1 is essential for nuclear Lamin-B structure and function and protects heterochromatin under mechanical stress. Cell Reports, 2021, 36, 109694.	6.4	15
108	Complexes formed by mutant p53 and their roles in breast cancer. Breast Cancer: Targets and Therapy, 2018, Volume 10, 101-112.	1.8	14

#	Article	IF	Citations
109	Mutant p53â€“Nrf2 axis regulates the proteasome machinery in cancer. Molecular and Cellular Oncology, 2017, 4, e1217967.	0.7	12
110	A simple and fast method for preparing single stranded DNA template suitable for sequencing. Nucleic Acids Research, 1987, 15, 10047-10047.	14.5	11
111	The evolutionary conserved gene C16orf35 encodes a nucleo-cytoplasmic protein that interacts with p73. Biochemical and Biophysical Research Communications, 2009, 388, 428-433.	2.1	11
112	Identification of a HLA-A*0201-restricted immunogenic epitope from the universal tumor antigen DEPDC1. OncoImmunology, 2017, 6, e1313371.	4.6	11
113	TGS1 mediates 2,2,7-trimethyl guanosine capping of the human telomerase RNA to direct telomerase dependent telomere maintenance. Nature Communications, 2022, 13, 2302.	12.8	11
114	Amplifying Tumorâ€“Stroma Communication: An Emerging Oncogenic Function of Mutant p53. Frontiers in Oncology, 2020, 10, 614230.	2.8	10
115	Cooperation of p53 Mutations with Other Oncogenic Alterations in Cancer. Sub-Cellular Biochemistry, 2014, 85, 41-70.	2.4	10
116	GDA, a web-based tool for Genomics and Drugs integrated analysis. Nucleic Acids Research, 2018, 46, W148-W156.	14.5	9
117	ETS-related gene (ERG) undermines genome stability in mouse prostate progenitors via Gsk3Î² dependent Nkx3.1 degradation. Cancer Letters, 2022, 534, 215612.	7.2	6
118	Improving pharmacological rescue of p53 function: RITA targets mutant p53. Cell Cycle, 2010, 9, 2059-2062.	2.6	5
119	p53 orchestrates calcium signaling in vivo. Cell Cycle, 2015, 14, 1343-1344.	2.6	4
120	FUS-dependent loading of SUV39H1 to OCT4 pseudogene-lncRNA programs a silencing complex with OCT4 promoter specificity. Communications Biology, 2020, 3, 632.	4.4	4
121	Anticancer innovative therapy congress: Highlights from the 10th anniversary edition. Cytokine and Growth Factor Reviews, 2021, 59, 1-8.	7.2	4
122	The Transcriptional Coactivator Yes-Associated Protein Drives p73 Gene-Target Specificity in Response to DNA Damage. Molecular Cell, 2005, 19, 429.	9.7	3
123	Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer. EMBO Molecular Medicine, 2014, 6, 295-295.	6.9	3
124	Multi-omics reveals global effects of mutant p53 gain-of-function. Cell Cycle, 2016, 15, 3009-3010.	2.6	3
125	Bridge-Induced Translocation between NUP145 and TOP2 Yeast Genes Models the Genetic Fusion between the Human Orthologs Associated With Acute Myeloid Leukemia. Frontiers in Oncology, 2017, 7, 231.	2.8	3
126	Immunohistochemical Characterization of a Renal Nephroblastoma in a <i>Trp</i>53-mutant and Prolyl Isomerase 1-deficient Mouse. Journal of Toxicologic Pathology, 2013, 26, 423-427.	0.7	2

#	Article	IF	Citations
127	Expression and subcellular localization of the bromodomain-containing protein 7 is a prognostic biomarker in breast cancer. Anti-Cancer Drugs, 2020, 31, 423-430.	1.4	2
128	Polo-like kinase 2: A new exploitable target to undermine mutant p53-dependent chemoresistance. Cell Cycle, 2012, 11, 438-438.	2.6	1
129	HIV-1 Integrase Binding to its Cellular Partners: A Perspective from Computational Biology. Current Pharmaceutical Design, 2014, 20, 3412-3421.	1.9	1
130	A mutant p53/Hif1Î±/miR-30d axis reprograms the secretory pathway promoting the release of a prometastatic secretome. Cell Stress, 2020, 4, 261-264.	3.2	1